News

Lunsumio remains in the body for several months after the last dose. Regular follow-up is essential to manage any lingering side effects and ensure a smooth transition off the treatment.
Results from the Phase III SUNMO trial show that the Lunsumio and Polivy combination achieved statistically significant ...
Lunsumio can cause overactivity of the immune system, a condition called hemophagocytic lymphohistiocytosis. HLH can be life-threatening and has led to death in people treated with Lunsumio.
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO [NCT05171647] study showing Lunsumio® (mosunetuzumab-axgb) administered ...
About Lunsumio® (mosunetuzumab) Lunsumio is a first-in-class CD20xCD3 T-cell-engaging bispecific antibody designed to target CD3 on the surface of T cells and CD20 on the surface of B cells.
Lunsumio and Polivy are a CD20×CD3 T-cell-engaging bispecific antibody and an anti-CD79b antibody-drug conjugate (ADC), respectively. Roche global product development head and chief medical ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO [ NCT05171647] study showing Lunsumio ® (mosunetuzumab-axgb) administered ...
New and Updated Data for Genentech’s Fixed-Duration Columvi and Lunsumio at ASH 2024 Reinforce Their Potential to Improve Outcomes for People With Lymphoma – Long-term data confirm fixed ...
Genentech’s Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma Business Wire Jun 20, 2025 ...
– Long-term data confirm fixed-duration Columvi and Lunsumio achieve durable remissions beyond the end of treatment, with real-world data suggesting reduced treatment-related travel burden due to less ...